Home > Insider Trading > Filing (0000899243-19-020029)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1680581	Fulcrum Therapeutics Inc.	FULC	Pharmaceutical Preparations (2834)	474839948

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1688325	Trv Gp Iv, Llc	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1688326	Third Rock Ventures Gp Iv, L.p.	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1688327	Third Rock Ventures Iv, L.p.	C/O Third Rock Ventures, Llc, 29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-07-22	2,261,904	$0.00	2,261,904	No	4	C	Direct
Common Stock	Acquisiton	2019-07-22	81,250	$16.00	2,343,154	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-07-22	15,833,333	$0.00	2,261,904	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct

Footnotes

On July 22, 2019, the Series A Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.